CSIMarket Company Name, Ticker, Suppliers, else..
 
Eton Pharmaceuticals Inc   (NASDAQ: ETON)
Other Ticker:  
 
 
Price: $14.2200 $-0.56 -3.789%
Day's High: $14.63 Week Perf: -7 %
Day's Low: $ 14.15 30 Day Perf: -1.18 %
Volume (M): 224 52 Wk High: $ 18.41
Volume (M$): $ 3,187 52 Wk Avg: $7.91
Open: $14.52 52 Wk Low: $3.03



 Market Capitalization (Millions $) 362
 Shares Outstanding (Millions) 25
 Employees 37
 Revenues (TTM) (Millions $) 38
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 10

Eton Pharmaceuticals Inc
Eton Pharmaceuticals Inc is a specialty pharmaceutical company that focuses on developing and commercializing innovative treatments for various diseases and disorders. The company's main emphasis is on developing products that have a high need in the market, yet are underserved or have limited competition. Eton Pharmaceuticals aims to offer cost-effective solutions that improve patient outcomes and enhance quality of life. They have a strong pipeline of products in development across multiple therapeutic areas, including neurology, hospital, and rare diseases.


   Company Address: 21925 W. Field Parkway, Suite 235 Deer Park 60010 IL
   Company Phone Number: 787-7361   Stock Exchange / Ticker: NASDAQ ETON


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALKS        0.67% 
AMRX        0.46% 
BHC        1.7% 
PBYI        8.33% 
TEVA   -3.65%    
VTRS   -1.08%    
• View Complete Report
   



Product Service News

Eton Pharmaceuticals Sets New Precedent in Rare Disease Treatment with Galzin? Acquisition,

Published Fri, Jan 3 2025 12:21 PM UTC

Eton Pharmaceuticals Takes Bold Step Forward in Fight Against Rare Diseases with Galzin Acquisition In a landmark move signaling its unwavering commitment to rare disease advocacy, Eton Pharmaceuticals, Inc. (NASDAQ: ETON) recently announced the acquisition of Galzin? (zinc acetate). This strategic decision, unveiled on January 3, 2025, positions Eton at the forefront of inn...
Clinical Study

Eton Pharmaceuticals? PKU GOLIKE Trial A Beacon of Hope for Patients and the Future of Metabolic Control

Published Sun, Dec 29 2024 3:26 PM UTC

In the rapidly evolving world of biopharmaceuticals, Eton Pharmaceuticals has recently set a new benchmark with the announcement of the final readout for its groundbreaking clinical trial of PKU GOLIKE. Garnering significant clinical and statistical improvement in metabolic control during prolonged fasting in patients with phenylketonuria (PKU), this trial?s findings promise...
Contract

Eton Pharmaceuticals Acquires Increlex to Enhance Treatment Options for Pediatric Patients with Severe IGF-1 Deficiency

Published Fri, Dec 20 2024 11:50 AM UTC

In December 2024, Eton Pharmaceuticals, Inc., a company renowned for its commitment to developing therapies for rare diseases, announced the successful acquisition of Increlex (mecasermin injection) from Ipsen S.A. This strategic move highlights Eton s dedication to addressing unmet medical needs in pediatric populations, specifically children suffering from severe primary i...
Contract

Eton Pharmaceuticals Expands Portfolio Through Acquisition of Increlex, Reinforcing Commitment to Rare Disease Patients

Published Thu, Oct 3 2024 10:30 AM UTC

In a significant move that underscores its commitment to patients with ultra-rare conditions, Eton Pharmaceuticals, Inc. has announced the acquisition of Increlex (mecasermin injection) from Ipsen. This strategic decision not only broadens Eton s product offerings but also aligns with its mission to develop and distribute medicines that can dramatically change lives.Increlex...
Management Announcement

Eton Pharmaceuticals' Hydrocortisone Oral Solution Prepares for FDA Decision as Share Price Rises

Published Mon, Jul 15 2024 8:05 PM UTC



In an exciting development for Eton Pharmaceuticals, the company recently announced that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ET-400, a Hydrocortisone Oral Solution. The Prescription Drug User Fee Act (PDUFA) target action date for the drug s approval is set for February 28, 2025. As Eton anticipates this dec...






Eton Pharmaceuticals Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com